ASRT - Assertio Therapeutics, Inc.
| Previous Close | 0.7299 |
| Open | 0.7300 |
| Bid | 0.7179 x 800 |
| Ask | 0.7192 x 1000 |
| Day's Range | 0.6900 - 0.7540 |
| 52 Week Range | 0.6900 - 5.7600 |
| Volume | 1,451,858 |
| Avg. Volume | 1,677,642 |
| Market Cap | 58.082M |
| Beta (3Y Monthly) | 1.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9700 |
| Earnings Date | Nov 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.50 |
- GlobeNewswire
Assertio Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
LAKE FOREST, Ill., Nov. 26, 2019 -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the 31st Annual Piper.
- GlobeNewswire
Assertio Therapeutics to Present at the 2019 Stifel Healthcare Conference
LAKE FOREST, Ill., Nov. 13, 2019 -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the Stifel Healthcare.
- Zacks
PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales
PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well. However, revenues fall year over year.
- Zacks
Assertio (ASRT) Surpasses Q3 Earnings Estimates
Assertio (ASRT) delivered earnings and revenue surprises of 4.35% and -6.93%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Assertio Therapeutics Announces Third-Quarter 2019 Results
-- Company Implements New Cost Savings Initiatives Expected to Deliver Annualized Savings of $20.0 Million -- -- Raises Full-Year 2019 Earnings Guidance Ranges -- -- Lowers.
- Simply Wall St.
How Much Did Assertio Therapeutics, Inc.'s (NASDAQ:ASRT) CEO Pocket Last Year?
In 2017 Art Higgins was appointed CEO of Assertio Therapeutics, Inc. (NASDAQ:ASRT). This analysis aims first to...
- PR Newswire
Ceridian HCM Holding, BJ's Wholesale Club Holdings Set to Join S&P MidCap 400; Oceaneering International, Covetrus to Join S&P SmallCap 600
NEW YORK , Oct. 30, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Tuesday, November 5 : ...
- Zacks
Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Assertio Therapeutics to Report Third-Quarter 2019 Financial Results After the Close of Markets on Wednesday, November 6, 2019
LAKE FOREST, Ill., Oct. 23, 2019 -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that it will release third-quarter 2019 financial results on Wednesday, November.
- Benzinga
The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 21.) Aprea Therapeutics Inc (NASDAQ: APRE ) AVITA ...
- GlobeNewswire
Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin
Assertio Therapeutics, Inc. (ASRT), today announced that its development partner West Therapeutic Development, LLC (West) has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for its injectable formulation of long-acting cosyntropin (synthetic adrenocorticotropic hormone, or ACTH). West is seeking approval for use as a diagnostic drug in the screening of patients presumed to have adrenocortical insufficiency. The primary focus of the CRL relates to the FDA determination that certain pharmacodynamic parameters were not adequately achieved.
- Benzinga
The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings
Biotech stocks continued to languish for a third straight week. Negative broader market sentiment and company-specific weakness weighed down on the sector. Pfenex Inc (NYSE: PFNX ) received FDA approval ...
- Simply Wall St.
How Does Assertio Therapeutics, Inc. (NASDAQ:ASRT) Affect Your Portfolio Volatility?
If you own shares in Assertio Therapeutics, Inc. (NASDAQ:ASRT) then it's worth thinking about how it contributes to...
- GlobeNewswire
Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors
Assertio Therapeutics, Inc. (ASRT) announced today that Dr. David Wheadon has been appointed to the Company’s Board of Directors. Dr. Wheadon is a former senior executive of AstraZeneca plc. “David is a globally recognized leader in healthcare and we are thrilled to have him join our Board of Directors,” said Arthur Higgins, President and CEO of Assertio.
- GlobeNewswire
Assertio Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference
LAKE FOREST, Ill., Sept. 26, 2019 -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the Annual Cantor.
- CNW Group
Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes
TORONTO and HOUSTON , Sept. 24, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced the appointment of Ms. Karen Dawes to the Board of Directors of Medicenna and the voting results from the Company's annual meeting of shareholders held today, September 24, 2019 in Toronto (the "Meeting"). A total of 36.15% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.
- Zacks
ASRT vs. ZTS: Which Stock Is the Better Value Option?
ASRT vs. ZTS: Which Stock Is the Better Value Option?
- Zacks
Top Ranked Value Stocks to Buy for September 9th
Top Ranked Value Stocks to Buy for September 9th
- Simply Wall St.
If You Had Bought Assertio Therapeutics (NASDAQ:ASRT) Stock Three Years Ago, You'd Be Sitting On A 94% Loss, Today
As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a while...
- Zacks
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
ASRT vs. ZTS: Which Stock Is the Better Value Option?
- GlobeNewswire
Assertio Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference
LAKE FOREST, Illinois, Aug. 20, 2019 -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the 17th Annual Morgan.
- Zacks
Assertio Therapeutics Enters Oversold Territory
Assertio Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Zacks
ASRT vs. PCRX: Which Stock Is the Better Value Option?
ASRT vs. PCRX: Which Stock Is the Better Value Option?
- GuruFocus.com
Assertio Therapeutics Inc (ASRT) Director, President and CEO Arthur J Higgins Bought $77,000 of ...
Director, President and CEO of Assertio Therapeutics Inc (30-Year Financial, Insider Trades) Arthur J Higgins (insider trades) bought 50,000 shares of ASRT on 08/12/2019 at an average price of $1.54 a share. Continue reading...
- GlobeNewswire
Assertio Therapeutics Announces Exchange Offer of $200 Million of its Currently Outstanding 2.50% Convertible Notes Due 2021
“We have worked hard to pay down our senior secured debt and with today’s announcement we have taken a significant step toward addressing our 2021 convertible debt. Pursuant to the Exchange Agreements, Assertio will exchange approximately $200 million aggregate principal amount of Exchanged Notes for a combination of (a) its new 5.00% Convertible Senior Notes due August 15, 2024 (the “New Convertible Notes”), (b) a cash payment plus accrued but unpaid interest on the Exchanged Notes, and (c) an agreed number of shares of Assertio’s common stock. The transactions are subject to customary closing conditions and are expected to close on August 13, 2019. The shares of Assertio’s common stock and the New Convertible Notes will be issued in private placements exempt from registration in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). Assertio will issue approximately $120 million aggregate principal amount of New Convertible Notes, pay an aggregate of approximately $30 million in cash and issue an aggregate of approximately 15.8 million shares of its common stock in the transactions.
